inbiome

🦠 Looking forward to #EBJIS2024! The European Bone and Joint Infection Society is bringing together great minds, and we are excited to be part of it. 🦴📚 Even more thrilled to share that the results of a study performed at Orthopädisches Spital Speising showing the benefits of Molecular Culture for joint infection diagnostics will be presented. Mark your calendars for Friday, 27th September at 16:15, where Dr. Sujeesh Sebastian will speak at the Free Paper Session J: Molecular techniques for microbiology diagnosis. Don’t miss it if you’re curious about the latest in microbiology diagnostics🧬🔍 Plus, the inbiome team will be at the booth, ready to chat and connect. If you’re around, come say hi—we’d love to meet you and talk about all things bone and joint infections! 👋 See you in Barcelona! 🚶♀️💬 #EBJIS2024 #inbiome

🌍 Celebrating Diversity the Roaring 20's Way! 🍸 Kicking off the weekend in style! At inbiome, we're proud to have a team that spans 9 different countries, and last night we celebrated this diversity with a Roaring 20s-themed cocktail event! 🥂Our talented interns mixed up special cocktails from their home countries, bringing a unique international flavor to the evening. It was a wonderful blend of cultures, collaboration, and fun! We are happy to foster an inclusive environment where diversity drives innovation—one sip at a time! 🍹 #Roaring20s #inbiome #Molecularculture

🎉👶 Hot off the Press! 👶🎉 Hey, fellow science enthusiasts! Our new protocol paper, "Assessing Diagnostic Performance of Molecular Culture for Neonatal Sepsis: Protocol of the CHAMPIONS Study," just got published in Diagnostics! 🍼🧪 Why does this matter? Well, diagnosing neonatal sepsis is challenging — nonspecific signs, unreliable blood markers, and long waits for lab results make it tough. Meanwhile, delaying antibiotics for truly infected infants can be dangerous, but starting them on uninfected babies isn’t great either. It disrupts gut microbiota development, leads to unnecessary hospital stays, and even contributes to multi-resistant organisms. 😬 So, what’s our plan? We’re testing out Molecular Culture® ID—our rapid, broad-range PCR-based test—to see if it can speed up and sharpen the diagnosis. The goal? To help clinicians quickly figure out which babies need antibiotics and which don’t, minimizing unnecessary treatments and keeping those tiny guts happy and healthy. Big thanks to co-authors Jip Groen, Martijn van der Kuip, Marc Benninga, Hendrik Niemarkt and Tim de Meij and collaborating institutions Amsterdam UMC, Maxima Medical Center, and Amsterdam Reproduction and Development—Inbiome's co-authors Martine Bos and Dries Budding couldn’t have asked for a better team to tackle this challenge. 💪❤️ Check out the full protocol on this link or click below: https://lnkd.in/ef4DttZZ #CHAMPIONSStudy #NeonatalSepsis #inbiome #MolecularCulture #StayCurious

🎉We are excited to announce that Emily has completed her internship at inbiome! She focused on improving IVF with our Molecular Culture product, significantly enhancing our understanding in this area. Fun fact: Emily is now part of ArtPred. We look forward to her continued success in healthcare. Thank you, Emily, for your hard work! 🌟 #inbiome #IVF #MolecularCulture #Research #Healthcare #Innovation

📢 We just wrapped up our Lean Six Sigma training where we tackled the workflow of a virtual pizza bakery! 🍕 Our team worked hard to streamline the process, cutting down inefficiencies and enhancing productivity. Check out the fun and engaging activities we did to achieve an efficient workflow! 💡 Did you know applying Lean Six Sigma methodologies can significantly improve operational processes? Our team certainly experienced the benefits firsthand. Many thanks to Reinders Folmer Consultancy #MolecularCulture #inbiome #efficiency #team #Lean4Teams

Research news from inbiome 🧑🔬 A new study in BMC Infectious Diseases used inbiome’s IS-pro technology to investigate if gut microbiota composition can help predict recurrent Clostridioides difficile infection (CDI).   Clostridioides difficile infection (CDI) is the main cause of diarrhoea linked to antibiotic use, affecting over 200.000 patients each year in the US alone. Even with proper treatment, 25-30% of patients have recurrent CDI, which can lead to severe disease and death. New treatments that reduce the risk of recurrence are available, but they are costly and not widely used.   If it was possible to identify which patients are most likely to have recurrent CDI, these effective yet expensive new drugs could be used more efficiently.   Previous prediction models based on clinical patient characteristics have been developed, but they failed in clinical practice. In this new study, it was shown that predictive models based on microbiota profiles made with IS-pro performed significantly better than models based on clinical parameters. This exciting finding indicates that the microbiota composition is the most important factor to take into account when identifying patients at risk for recurrent CDI.   While the results are very valuable and encouraging, we are not quite there yet in creating a prediction model that is ready for clinical use. The gut microbiota composition is so unique to each patient individually, that a larger patient group will be required to create a robust prediction model that could be universally used. The study was carried out at Amsterdam UMC, led by main author Tess van Rossen, along with co-authors Yvette H. van Beurden, Johannes A. Bogaards, Chris JJ Mulder, Christina Vandenbroucke-Grauls, and inbiome CEO, Dries Budding. Thanks to ZonMw and NWO (Dutch Research Council) for providing the funding opportunities for this study. https://lnkd.in/efSWMdg2

🌟 Meet Inge Balqis, a master's student in Science, Business, and Innovation at VU! 🌟 During her internship at Inbiome, Inge delved into the potential of value-based pricing to enhance the adoption of broad-range PCR (BR-PCR) for diagnosing bacterial infections. Her key findings include: ✅ Identifying user requirements for the operational and economic integration of BR-PCR. ✅ Highlighting diagnostic uncertainties where BR-PCR can add significant value, guiding future validation studies. 💡 Inge's insights formed the basis for quantifying value propositions into monetary terms, helping users understand the cost-benefit ratio of BR-PCR and make informed decisions about its use. Great job, Inge! Your work is a vital step towards innovative and efficient bacterial infection diagnostics. 👏

🤓 Nerd Alert @ the inbiome HQ 🤓 Take a quick peak at the weekly research gathering of our team! Each thursday morning all team divisions (IT, R&D, QA, Lab Operations, Commercial, Leadership) sit in one room to explore together either our own research questions or interesting science around us. While two weeks ago we discussed the latest experiments of one the sample types we are studying, today our founders brought us the freshest bits from the ASM Microbe Conference in Atlanta. New technologies, potential partnerships...so much inspiration to keep on radically accelerating human healthcare 🚀 #inbiome #MolecularCulture #fastdiagnostics #nerdalert

Inbiome will be present at the ASM in Atlanta the coming days! #ASM #Diagnostics #Microbiology

It’s a day of insightful interactions at #ECCMID! Our team at inbiome is engaging with healthcare professionals, sharing how our molecular diagnostics accelerate the path to effective treatment. By rapidly identifying pathogens, we empower clinicians to make informed decisions, ensuring better patient outcomes #ESCMIDglobal #MolecularCulture #fastdiagnostics #inbiome